Investigating the efficacy and safety of Myrtus nasal spray in controlling the symptoms of patients with mild COVID-19
Phase 3
- Conditions
- COVID-19.Covid-19U07.1
- Registration Number
- IRCT20080901001165N63
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Age: equal or more than 18 years;
The patient have written consciously and freely consent to participate in the study;
The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19.
Confirmed diagnosis of COVID-19, with RT-PCR confirmation.
Less than 7 days have passed since the onset of symptoms.
Exclusion Criteria
History of allergy to this nasal spray ingredients;
The patient is in another clinical trial at the same time;
The patient needs to receive medical care from the inpatient care;
Pregnancy;
Lactation.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms (dry cough). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Baseline (before the initiation of intervention), and day 7 from the initiation. Method of measurement: Thermometer.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: Before the intervention initiation (baseline) and day 7. Method of measurement: Physical examination.;Need to be hospitalized. Timepoint: Before the intervention initiation (baseline) and day 7. Method of measurement: Question from the patient.;Mortality. Timepoint: Day 28 from the initiation. Method of measurement: Clinical assessment.